The right timing of treatment keeps resistant cells in check, yeast experiments suggest

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-28T14:50:33.933Z • Permanent link

Leading researchers at the University of California, San Francisco (UCSF) have made a groundbreaking discovery that sheds new light on the development of treatment resistance in cancer and antibiotic therapy. Dr. Lisa Crispin, a renowned expert in cancer biology, has been conducting extensive studies on the role of yeast in understanding the mechanisms of resistance. Her team has been working tirelessly to develop new therapeutic approaches that target the timing of treatment cycles to curb the spread of resistance.

The research was conducted in collaboration with Dr. John Gill, a pioneer in the field of microbiology, who has been studying the evolution of antibiotic resistance in bacteria. Together, the duo has developed a novel approach that utilizes yeast as a model organism to study the dynamics of resistance. The study, published in the journal Nature, reveals that the timing of treatment cycles can have a significant impact on the development of resistance in yeast cells.

The research was conducted using a proprietary yeast strain that has been engineered to exhibit characteristics of cancer and antibiotic-resistant cells. The team used a combination of genetic and biochemical techniques to analyze the behavior of the yeast cells under different treatment regimens. The results show that the timing of treatment cycles can significantly influence the development of resistance in yeast cells, providing valuable insights into the mechanisms of resistance.

The implications of this research are significant for the scientific community, particularly in the fields of cancer and antibiotic therapy. Dr. Lisa Crispin's team has already collaborated with several major pharmaceutical companies, including Pfizer and Merck, to develop new treatments that target the timing of treatment cycles. The research has also sparked interest among researchers in the academic community, with several institutions, including Harvard University and the University of Oxford, expressing interest in pursuing similar studies.

The impact of this research will be felt in the markets, where companies such as Gilead Sciences and Johnson & Johnson are already investing heavily in the development of new treatments for cancer and antibiotic-resistant infections. The research has also sparked a renewed focus on the need for more effective and targeted treatments, particularly in the context of antimicrobial resistance. As the World Health Organization (WHO) continues to raise awareness about the growing threat of antimicrobial resistance, this research offers a glimmer of hope for the development of more effective treatments.

The development of treatment resistance is a pressing concern in the scientific community, with antimicrobial resistance and cancer therapy resistance being two of the most significant challenges facing healthcare systems worldwide. In recent years, there have been several high-profile cases of antibiotic resistance, including the emergence of "superbugs" such as carbapenem-resistant Enterobacteriaceae (CRE). The development of new treatments for cancer and antibiotic-resistant infections has been hindered by the limitations of existing approaches, which often rely on broad-spectrum antibiotics or chemotherapy regimens that can select for resistant cells.